The purpose of this clinical trial is to compare the use of an investigational medicine and lenalidomide vs. lenalidomide alone as maintenance in patients with newly diagnosed multiple myeloma who are minimal residual disease positive after an autologous stem cell transplant.
This trial is currently open and accepting patients.
Participants in this study will be randomly assigned to one of two groups (also called arms). Participants in Arm A will receive daratumumab and lenalidomide, while participants in Arm B will receive lenalidomide alone.
Participants in either arm will receive their therapies in 28 day cycles, and may receive up to 36 cycles as long as their myeloma doesn’t get worse or they don’t experience bad side effects.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Enrollment: 214 patients (estimated)View More
View all clinical trial locations sorted by state.
San Francisco, CA
La Jolla, CA
Los Angeles, CA
Fort Collins, CO
New Haven, CT
Fort Wayne, IN
Grand Rapids, MI
Kansas City, MO
New Brunswick, NJ
Lake Success, NY
New York, NY
New York, NY
Chapel Hill, NC
West Reading, PA
Boiling Springs, SC
San Antonio, TX
Salt Lake City, UT
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message